4. Basics of Immunotherapy

5. Potential Therapeutic Targets

6. Common Checkpoint Molecules in Immunotherapy

7. Nivolumab

8. Pembrolizumab

9. Toxicity With Checkpoint Inhibitors

10. Key Points Regarding Toxicity

11. Considerations for Toxicity Management

12. Completed Studies With First-Line Checkpoint Inhibitors

13. First-Line Anti-PD-L1: Durvalumab

14. CheckMate 012 Efficacy Results

15. CheckMate 012 Safety Results

16. CheckMate 568

17. KEYNOTE-021 Design

18. KEYNOTE-021 Efficacy Results

19. KEYNOTE-021 Safety Results

20. Other Treatment Considerations

21. POPLAR Study Outcomes

22. Additional Combination Studies

23. PD-L1 Testing

24. IFNγ as a Biomarker in Durvalumab in NSCLC

25. Additional Second-Line Checkpoint Inhibitor Combination Studies

26. Concluding Remarks

27. Abbreviations

28. Abbreviations